James W. Janetka

Has grant

Washington University School of Medicine

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Open

Optimizing CDPK1 inhibitors for chronic toxoplasmosis

Open Date: 2022-03-01

Close Date: 2027-02-28

Grant: Close

Integrative approach for accelerating filarial worm drug discovery to treat river blindness

Open Date: 2021-09-30

Close Date: 2025-06-30

Grant: Close

Development of small molecule inhibitors of metabolic enzymes as broad spectrum anthelmintic drugs

Open Date: 2021-03-11

Close Date: 2026-02-28

Grant: Close

Innovative Strategies to Combat Antibiotic-resistant Infections

Open Date: 2021-03-01

Close Date: 2026-02-28

Grant: Close

Inhibitors of pro‐HGF activation overcome resistance to anti‐EGFR therapy

Open Date: 2019-09-17

Close Date: 2021-03-31

Articles (7)

Year:

2024

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (2)

Lisa McLellan

Assistant Professor

Purdue University Fort Wayne

UNITED STATES

View details

Makedonka Mitreva

Professor

Washington University in Saint Louis School of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

James W. Janetka

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (7)

Discovery of Orally Bioavailable FmlH Lectin Antagonists as Treatment for Urinary Tract Infections

An Integrated Approach to Identify New Anti-Filarial Leads to Treat River Blindness, a Neglected Tropical Disease

A host receptor enables type 1 pilus-mediated pathogenesis of Escherichia coli pyelonephritis

Macrocyclic Inhibitors of HGF-Activating Serine Proteases Overcome Resistance to Receptor Tyrosine Kinase Inhibitors and Block Lung Cancer Progression

A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells

Optimizing Pyrazolopyrimidine Inhibitors of Calcium Dependent Protein Kinase 1 for Treatment of Acute and Chronic Toxoplasmosis

Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254)

Collaborators (2)

Lisa McLellan

Makedonka Mitreva

Make your next move.